Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Leases (2020 - 2025)

Apellis Pharmaceuticals has reported Operating Leases over the past 6 years, most recently at $11.9 million for Q4 2025.

  • Quarterly results put Operating Leases at $11.9 million for Q4 2025, up 17.12% from a year ago — trailing twelve months through Dec 2025 was $11.9 million (up 17.12% YoY), and the annual figure for FY2025 was $11.9 million, up 17.12%.
  • Operating Leases for Q4 2025 was $11.9 million at Apellis Pharmaceuticals, down from $13.7 million in the prior quarter.
  • Over the last five years, Operating Leases for APLS hit a ceiling of $19.9 million in Q1 2021 and a floor of $8.3 million in Q2 2025.
  • Median Operating Leases over the past 5 years was $12.6 million (2023), compared with a mean of $13.5 million.
  • Biggest five-year swings in Operating Leases: skyrocketed 78.16% in 2021 and later dropped 28.83% in 2023.
  • Apellis Pharmaceuticals' Operating Leases stood at $17.1 million in 2021, then fell by 15.98% to $14.4 million in 2022, then dropped by 20.19% to $11.5 million in 2023, then fell by 10.94% to $10.2 million in 2024, then grew by 17.12% to $11.9 million in 2025.
  • The last three reported values for Operating Leases were $11.9 million (Q4 2025), $13.7 million (Q3 2025), and $8.3 million (Q2 2025) per Business Quant data.